Why this Wall Street hedge fund legend sold VRX and GILD?
ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.
Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.
Cory Kasimov is enthusiastic on GILD’s CAR-T therapy Yescarta as well as M&A strategy.
Gilead Sciences, Inc. (NASDAQ:GILD) shares fell nearly 4% in the extended session Thursday after the …
Cory Kasimov: GILD’s Phase II study data may be early, but first signs speak to a well-tolerated treatment.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Did this $4 billion fund make the right call on these two soaring biotechs?
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved …